AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00940589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets, with identical features to the Circadin tablets
Study NCT02636582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02636582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02636582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelipepimut-S Plus GM-CSF Vaccine
Description: Given ID
Study NCT02636582 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Given ID
Study NCT02636582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT00426244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment
Description: OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
Study NCT00426244 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Ultrasound
Description: In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects.
Study NCT01801228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study NCT02636582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT02291120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Study NCT02291120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Study NCT01801228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Study NCT00751400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: Consumer use of Extended Release Naproxen Sodium
Study NCT04520646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: empagliflozin of 10mg/day is added on the basis of primary care
Study NCT03967613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional eletrical stimulation
Description: Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
Study NCT01930136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction (25%)
Study NCT01930136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad libitum health diet
Study NCT04185090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID1803
Description: Amlodipine 10mg/Valsartan 160mg
Study NCT02600039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELTGOL
Description: Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
Study NCT02600039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELTGOL
Description: Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
Study NCT02600039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acapella
Description: Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
Study NCT02600039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella
Description: Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
Study NCT01900717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified
Study NCT01900717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
Study NCT02199210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prompting forethought
Description: Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
Study NCT04133129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Volume-High Intensity Interval Training
Description: On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
Study NCT04133129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
Study NCT01782248 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnary and IRM
Study NCT04185090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID1801
Description: Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
Study NCT01454141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Three sessions of CCT.
Study NCT04185090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ID1803+ID1801
Description: Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
Study NCT00631774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna SR
Description: Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
Study NCT04670185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIP SAMBA
Description: Behavioral parent management training
Study NCT03413280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
Study NCT03413280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Rectus sheath block
Description: Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
Study NCT03413280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
Study NCT03413280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Description: Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
Study NCT02830100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy volunteers
Description: Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
Study NCT02830100 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT01222546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH5132799
Study NCT03162770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
Study NCT03298581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate
Description: Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
Study NCT01454141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Vision Task
Description: Three sessions of PVT.
Study NCT01923272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore Device
Description: Active stimulation to the vagal nerve
Study NCT01923272 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore Device
Description: Active stimulation to the vagal nerve
Study NCT01923272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaCore
Description: Active AlphaCore treatment
Study NCT01923272 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AlphaCore
Description: Active AlphaCore treatment
Study NCT02415036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delcath Hepatic Delivery System
Study NCT02415036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00568165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile team
Description: a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
Study NCT00568165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT04159311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathy
Description: testing osteopathy Vs Treating osteopathy
Study NCT04159311 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathy
Description: testing osteopathy Vs Treating osteopathy
Study NCT00908843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hydration with bicarbonate
Description: Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
Study NCT00908843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hydration with Sodium solution
Description: Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
Study NCT03383341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cricket Protein Powder
Description: Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
Study NCT03383341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
Study NCT03736772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3090106
Description: Administered SC
Study NCT03736772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01171560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal intubation
Description: The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
Study NCT01713023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The same described in Arm description
Study NCT01713023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: The same described in Arm description
Study NCT02891655 — intervention group
Intervention type: OTHER
Intervention: immuno-histo-chemical analysis
Description: in vitro immuno-histo-chemical analysis of corneal epithelium
Study NCT01140451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
Study NCT03629457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Mindful Self-Compassion
Description: Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
Study NCT04165707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keyto device + app
Description: Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
Study NCT04165707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers app
Description: The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
Study NCT04423809 — intervention group
Intervention type: OTHER
Intervention: clinical assessment
Description: assessment of caregivers suffering when a family member is hospitalized
Study NCT01143753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5212054
Description: Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
Study NCT04091529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADIOFREQUENCY ABLATION OF UTERINE MYOMAS
Description: The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study NCT01041755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Description: a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
Study NCT01981590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.
Description: Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
Study NCT00434252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered by IV infusion on the first day of each 3-week cycle
Study NCT04683250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0953/HM06
Description: Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
Study NCT04683250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0953/HM06
Description: Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
Study NCT03500432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia of trnasperineal prostate biopsy
Description: three different block site with lidocaine
Study NCT01041755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactose
Description: a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
Study NCT03500432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia of trnasperineal prostate biopsy
Description: three different block site with lidocaine
Study NCT02697474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvax B®: Hepatitis B vaccine
Description: 0.5 mL, Intramuscular
Study NCT02538913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
Study NCT02538913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
Study NCT02538913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
Study NCT01970098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose
Description: 28 weeks
Study NCT01970098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Description: 28 weeks
Study NCT01970098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 28 weeks